Sun Pharma faces a delay in the U.S. launch of its drug Leqselvi due to a preliminary injunction by the New Jersey court, pending further legal proceedings or patent expiration in December 2026. The company plans to appeal the decision while considering a potential settlement with Incyte.
| Subscribe To Our Free Newsletter |
